Phase I Study of Sequential Administration of Topotecan and 5-Fluorouracil in Patients with Advanced Malignancies

REFERENCES

• Liu L.F. DNA Topoisomerase Poisons as Antitumor Drugs. Annu. Rev. Biochem. 1989; 58: 351–375
   PubMed Web of Science ®Google Scholar
• D'Arpa P., Lui L.F. Topoisomerase-Targeting Antitumor Drugs. Biochem. Biophys. Acta 1989; 989: 163–177
   PubMed Web of Science ®Google Scholar
• Wall M.E., Wane M.C., Cook C.E., Palmer K.H., McPhail H.T., Sim G.A. Plant Antitumor Agents. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata. J. Am. Chem. Soc. 1966; 88: 3888–3890
   Web of Science ®Google Scholar
• Hsiang Y.H., Hertzberg R., Hecht S., Liu L.F. Camptothecin Induces Protein-Linked DNA Breaks via Mammalian DNA Topoisomerase I. J. Biol. Chem. 1985; 260: 14873–14878
   PubMed Web of Science ®Google Scholar
• Zhang H., D'Arpa P., Lui L.F. A Model for Tumor Cell Killing by Topoisomerase Poisons. Cancer Cells 1990; 2: 23–27
   PubMed Web of Science ®Google Scholar
• Hageboutros A., Hudes G.R., Greene F., LaCreta F., Brennan J., O'Dwyer P.J. Phase I Trial of Fluorouracil Modulation by N-Phosphonacetyl-l-Asparate and 6-Methylmercaptopurine Ribonucleoside (MMPR), and Leucovorin in Patients with Advanced Cancer. Investig. New Drugs 1997; 15: 139–143
   PubMed Web of Science ®Google Scholar
• Speigelman S., Sawyer R., Nayak R., Ritzi E., Stolfi R., Martin D. Improving the Antitumor Activity of 5-Fluorouracil by Increasing Its Incorporation into RNA via Metabolic Modulation. Proc. Natl Acad. Sci. USA 1980; 77: 4966–4970
   PubMed Web of Science ®Google Scholar
• Nitiss J., Wang J.C. DNA Topoisomerase-Targeting Antitumor Drugs Can Be Studied in Yeast. Proc. Natl Acad. Sci. USA 1988; 85: 7501–7505
   PubMed Web of Science ®Google Scholar
• Eng W.K., Faucette L., Johnson R.K., Sternglanz R. Evidence that DNA Topoisomerase I Is Necessary for the Cytotoxic Effects of Camptothecin. Mol. Pharmacol. 1988; 34: 755–760
   PubMed Web of Science ®Google Scholar
• Thrash C., Voelkeki K., DiNardo S., Sternglanz R. Identification of Saccharamyces cerevisiae Mutants Deficient in DNA Topoisomerase I Activity. J. Biol. Chem. 1984; 259: 1357–1377
   PubMedGoogle Scholar
• Ardizzoni A., Hansen H., Dombernowsky P., Gamucci T., Kaplan S., Postmus P., Giaccone G., Shaefer B., Wanders J., Verweij J. Topotecan, a New Active Drug in the Second-Line Treatment of Small-Cell Lung Cancer: A Phase II Study in Patients with Refractory and Sensitive Disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J. Clin. Oncol. 1997; 15: 2090–2096
   PubMed Web of Science ®Google Scholar
• Schiller J.H., Kim K., Hutson P., DeVore R., Glick J., Stewart J., Johnson D. Phase II Study of Topotecan in Patients with Extensive-Stage Small-Cell Carcinoma of the Lung. J. Clin. Oncol. 1996; 14: 2345–2352
   PubMed Web of Science ®Google Scholar
• Kudelka A., Tresukosol D., Edwards C., Freedman R.S., Levenback C., Chantarawiroj P., Gonzalez de Leon C., Kim E.E., Madden T., Wallin B., Hord M., Verschraegen C., Raber M., Kavanagh J.J. Phase II Study of Intravenous Topotecan as a 5-Day Infusion for Refractory Epithelial Ovarian Carcinoma. J. Clin. Oncol. 1996; 14: 1552–1557
   PubMed Web of Science ®Google Scholar
• Robert F., Soong S.J., Wheeler R.H. A Phase II Study of Topotecan in Patients with Recurrent Head and Neck Cancer: Identification of an Active New Agent. J. Clin. Oncol. 1997; 20: 298–302
   PubMed Web of Science ®Google Scholar
• Eisenhatter E.A., Wainman N., Boos G., MacDonald D., Bramwell V. Phase II Trials of Topotecan in Patients with Malignant Glioma and Soft Tissue Sarcoma. Proc. Am. Soc. Clin. Oncol. 1994; 13: A488
   Google Scholar
• Hudes G.R., Kosierowski R., Greenberg R., Ramsey H.E., Fox S.C., Ozols R.F., McAleer C.A., Giantono B.J. Phase II Study of Topotecan for Hormone-Refractory Prostate Cancer. Investig. New Drugs 1995; 13: 235–240
   PubMed Web of Science ®Google Scholar
• Ilson D., Motzer R.J., O'Moore P., Manus D., Bosl G.J. A Phase II Trial of Topotecan in Advanced Renal Cell Carcinoma. Proc. Am. Soc. Clin. Oncol. 1993; 12: A779
   Google Scholar
• Lynch T.J., Jr., Kalish L., Strauss G., Elias A., Skarin A., Shulman L.N., Posner M., Frei E., III. Phase II Study of Topotecan in Metastatic Non-Small Cell Lung Cancer. J. Clin. Oncol. 1994; 12: 347–352
   PubMed Web of Science ®Google Scholar
• Perez-Soler R., Fossella F.V., Glisson B.S., Lee J.S., Murphy W.K., Shin D.M., Kemp B.L., Lee J.J., Kane J., Robinson. R.A., Lippman S.M., Kurie J.M., Huber M.H., Raber M.N., Hong W.K. Phase II Study of Topotecan in Patients with Advanced Non-Small Cell Lung Cancer Previously Untreated with Chemotherapy. J. Clin. Oncol. 1996; 14: 503–513
   PubMed Web of Science ®Google Scholar
• Sugarman S.M., Pazdur R., Daugherty K., Evans D., Winn R., Dubovsky D., Goodwin J.W., Abbruzzese J.L. A Phase II Trial of Topotecan (TPT) for the Treatment of Unresectable Pancreatic Cancer (PC). Proc. Am. Soc. Clin. Oncol. 1994; 13: A684
   Google Scholar
• Stevenson J.P., Scher R.M., Kosierowski R., Fox S.C., Simmonds M., Yao K.S., Green F., Broom C., Fields S.Z., Krebs J.B., O'Dwyer P.J. Phase II Trial of Topotecan as a 21-Day Continuous Infusion in Patients with Advanced or Metastatic Adenocarcinoma of the Pancreas. Eur. J. Cancer 1998; 34: 1358–1362
   PubMed Web of Science ®Google Scholar
• Sugarman S.M., Ajani J.A., Daugherty K., Winn R., Lanzotti V., Bearden J.D., Abbruzzese J.L. A Phase II Trial of Topotecan for the Treatment of Advanced Measurable Colorectal Cancer. Proc. Am. Soc. Clin. Oncol. 1994; 13: 225
   Google Scholar
• Rowinsky E., Kaufmann S., Baker S.D., Grochow L.B., Chen T.L., Peereboom D., Bowliing M.K., Sartorius S.E., Ettinger D.S., Forastiere A.A., Donehower R.C. Sequences of Topotecan and Cisplatin: Phase I, Pharmacologic, and In Vitro Studies to Examine Sequence Dependence. J. Clin. Oncol. 1996; 14: 3074–3084
   PubMed Web of Science ®Google Scholar
• Rothenberg M.L., Burris H.A., III, Eckardt J.R., Rinaldi D.A., Weiss G.R., Smith S., Jones K., Johnson R.K., Von Hoff D.D. Phase I/II Study of Topotecan and Cisplatin in Patients with Non-Small Cell Lung Cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 1993; 12: 156
   Google Scholar
• Miller A.A., Hargis J.B., Lilenbaum R.C., Fields S.Z., Rosner G.L., Schilsky R.L. Phase I Study of Topotecan and Cisplatin in Patients with Advanced Solid Tumors: A Cancer and Leukemia Group B Study. J. Clin. Oncol. 1994; 12: 2743–2750
   PubMed Web of Science ®Google Scholar
• Eckardt J.R., Burris H.A., Rodriguez G.A., Fields S.M., Rothenberg M.L., Moore T.D., Smith S.C., Ganapathi R., Weiss G.R., Johnson R.K., Kuhn J.G., Von Hoff D.D. A Phase I Study of the Topoisomerase I and II Inhibitors Topotecan and Etoposide. Proc. Am. Soc. Clin. Oncol. 1993; 12: 137
   Google Scholar
• Lilenbaum R.C., Miller A.A., Batist G., Bernard S., Hollis D.R., Rosner G.L., Egorin M.J., Schilsky R.L., Ratain M.J. Phase I and Pharmacologic Study of Continuous Infusion Topotecan in Combination with Cisplatin in Patients with Advanced Cancer: a Cancer and Leukemia Group B Study. J. Clin. Oncol. 1998; 16: 3302–3309
   PubMed Web of Science ®Google Scholar
• Tolcher A.W., O'Shaughnessy J.A., Weiss R.B., Zujewski J., Myhand R.C., Schneider E., Hakim F., Gress R., Goldspiel B., Noone M.H., Brewster L.R., Gossard M.R., Cowan K.H. A Phase I Study of Topotecan Followed Sequentially by Doxorubicin in Patients with Advanced Malignancies. Clin. Cancer Res. 1997; 3: 755–760
   PubMed Web of Science ®Google Scholar
• Graham M.V., Jahanzeb M., Dresler C.M., Cooper J.D., Emami B., Mortimer J.E. Results of a Trial with Topotecan Dose Escalation and Concurrent Thoracic Radiotherapy for Locally Advanced Inoperable Non-small Cell Lung Cancer. Int. J. Radiat. Oncol. Biol. Phys. 1996; 36: 215–220
   Google Scholar
• Juan C., Hwang J.L., Lui A.A., Whang-Peng J., Knutsen T., Huebner K., Crose C.M., Zhang H., Wang J.C., Liu L.F. Human DNA Topoisomerase I Is Encoded by a Single-Copy Gene That Maps to Chromosome Region 20q12-13.2. Proc. Natl Acad. Sci. USA 1988; 85: 8910–8913
   PubMed Web of Science ®Google Scholar
• Raymond E., Burris H.A., Rowinsky E.K., Eckhardt J.R., Rodriguez G., Smith L., Weiss G., Von Hoff D.D. Phase I Study of Daily Times Five Topotecan and Single Injection of Cisplatin in Patients with Previously Untreated Non-small-Cell Lung Carcinoma. Ann. Oncol. 1997; 8: 1003–1008
   PubMed Web of Science ®Google Scholar
• Arbuck S.G., Takimoto C.H. An Overview of Topoisomerase-I-Targeting Agents. Semin. Hematol. 1998; 35(3 Suppl. 4)3–12
   PubMed Web of Science ®Google Scholar
• Abang A.M. The Clinical Pharmacology of Topoisomerase I Inhibitors. Semin. Hematol. 1998; 35(3 Suppl. 4)13–21
   PubMed Web of Science ®Google Scholar
• Zamboni W.C., Egorin M.J., Van Echo D.A., Day R.S., Meisenberg B.R., Brooks S.E., Doyle L.A., Nemieboka N.N., Dobson J.M., Tait N.S., Tkaczuk K.H. Pharmacokinetic and Pharmacodynamic Study of the Combination of Docetaxel and Topotecan in Patients with Solid Tumors. J. Clin. Oncol. 2000; 18: 3288–3294
   PubMed Web of Science ®Google Scholar
• Taron M., Abad A., Mate J.L., Sarries C., Lopez M.P., Barnadas A., Rosell R. Schedule Dependency of the Synergism Between Topotecan 5-Fluorouracil and Tomudex in HT29 and LoVo Human Adenocarcinoma Cell Lines. Proc. Am. Soc. Clin. Oncol. 1996; 15: A1601
   Google Scholar
• Kaufmann S.H., Peereboom D., Buckwalter C.A., Svingen P.A., Grochow L.B., Donhower R.C., Rowinsky E.K. Cytotoxic Effects of Topotecan Combined with Various Anticancer Agents in Human Cancer Cell Lines. J. Natl Cancer Inst. 1996; 88: 734–741
   PubMed Web of Science ®Google Scholar
• Cheng M-F., Chatterjee S., Berger N.A. Schedule-Dependent Cytotoxicity of Topotecan Alone and in Combination Chemotherapy Regimens. Oncol. Res. 1994; 6: 269–279
   PubMed Web of Science ®Google Scholar